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Animal modelProtein tyrosine kinases (PTKs) coordinate a broad spectrum of cellular responses to extracellular stimuli and cell–
cell interactions during development, tissue homeostasis, and responses to environmental challenges. Thus, an un-
derstanding of the regulatory mechanisms that ensure physiological PTK function and potential aberrations of
these regulatory processes during diseases such as cancer are of broad interest in biology and medicine. Aside
from the expected role of phospho-tyrosine phosphatases, recent studies have revealed a critical role of covalent
modiﬁcation of activated PTKs with ubiquitin as a critical mechanism of their negative regulation. Members of
the Cbl protein family (Cbl, Cbl-b and Cbl-c in mammals) have emerged as dominant “activated PTK-selective”
ubiquitin ligases. Structural, biochemical and cell biological studies have established that Cbl protein-dependent
ubiquitination targets activated PTKs for degradation either by facilitating their endocytic sorting into lysosomes
or by promoting their proteasomal degradation. This mechanism also targets PTK signaling intermediates that be-
come associated with Cbl proteins in a PTK activation-dependent manner. Cellular and animal studies have
established that the relatively broadly expressed mammalian Cbl family members Cbl and Cbl-b play key physio-
logical roles, including their critical functions to prevent the transition of normal immune responses into autoim-
mune disease and as tumor suppressors; the latter function has received validation from human studies linking
mutations in Cbl to human leukemia. These newer insights together with embryonic lethality seen in mice with
a combined deletion of Cbl and Cbl-b genes suggest an unappreciated role of the Cbl family proteins, and by impli-
cation the ubiquitin-dependent control of activated PTKs, in stem/progenitor cell maintenance. Future studies of
existing and emerging animal models and their various cell lineages should help test the broader implications of
the evolutionarily-conserved Cbl family protein-mediated, ubiquitin-dependent, negative regulation of activated
PTKs in physiology and disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Phosphorylation of proteins on tyrosine residues is an evolutionarily
conservedmechanism used by higher eukaryotes to alter the activity of
cellular pathways in response to changes in extracellular environment.
This fundamentally simple biochemical process, mediated by proteinh in Cancer and Allied Diseases,
ka Medical Center Omaha, NE
59 4651.
l rights reserved.tyrosine kinases (PTKs), serves as an initial trigger in cellular activation
processes whose downstream components include other major signal
transduction enzyme cascades such as serine/threonine kinases, lipid
kinases, phosphatases, phospholipases, small GTPases and other path-
ways. PTK-mediated signaling ensures orderly cell–environment and
cell–cell interactions during development, tissue homeostasis, tissue re-
pair and remodeling, as well as protection against pathogens. It is
therefore not surprising that deregulation of PTK-initiated signal trans-
duction is a major cause of human diseases such as cancer [1]. Given
their critical importance in signal transduction cascades that regulate
normal development and homeostasis in higher organisms, as well as
the causal linkage of their aberrant activities to human diseases,
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interest in biology and medicine.
2. Protein tyrosine kinases as key mediators of trans-membrane
signaling
2.1. Both receptor and non-receptor protein tyrosine kinases mediate
trans-membrane signaling
58 of the 90 PTKs in the human genome are trans-membrane recep-
tors (referred to as receptor tyrosine kinases or RTKs) and are therefore
directly poised for signal transduction in response to extracellular cues.
Classicalmembers of this family include growth factor receptors such as
platelet-derived growth factor receptor (PDGFR) and epidermal growth
factor receptor (EGFR). However, RTKs are now known to play crucial
roles in essentially all developmental and homeostatic signaling path-
ways triggered by interactionswith soluble or cell-surface associated li-
gands [1]. Nearly all of the remaining PTKs, the so-called non-receptor
PTKs, are also involved in membrane receptor-initiated signaling
through their constitutive or inducible association with cell surface
receptors. For example, members of the Src-family of PTKs associate
with antigen receptors on immune cells and members of the JAK-
family of PTKs with cytokine receptors; in each case, non-covalently
associated PTKs are essential for cellular activation upon receptor en-
gagement, as demonstrated by naturally-occurring or engineered mu-
tations of genes encoding these PTKs [2,3]. Thus, PTKs serve as
essentialmembrane-proximal receptor signal transducers. Importantly,
cell surface receptors with intrinsic or associated PTK activity common-
ly serve as biochemical or functional partners of other cell surface
receptors such as G-protein coupled receptors (GPCRs), integrins and
others, and are also activated by altered metabolic states of cells, such
as oxidative stress. These collaborative interactions of PTKs further
expand their critical roles to essentially every physiological response
in higher eukaryotes [1].
2.2. Tyrosine phosphorylation-dependent signaling
Similar to serine/threonine phosphorylation, tyrosine phosphoryla-
tion can directly regulate enzymatic activity as exempliﬁed by the phos-
phorylation of activation loops of PTKs. Importantly, phosphotyrosine
(pY)-containing peptide sequences generated on PTKs themselves or
on their interacting partners serve as docking sites that are recognized
by Src-Homology 2 (SH2) and phosphotyrosine-binding (PTB) domains
on signaling proteins. These interactions promote the recruitment of
key regulatory and/or enzymatic components of signaling pathways
such as Ras-Erk, PI3-kinase and PLCγ tomembrane-associated activated
receptors resulting in the activation of these downstream pathways [1].
Given the primary role of phosphorylation-dependent regulation of sig-
naling protein complex formation and subsequent activation of enzy-
matic cascades, dephosphorylation by phosphotyrosine phosphatases
(PTPs) is thought to provide one mechanism to negatively regulate
PTK-dependent cellular activation. Notably, however, only in a limited
number of cases have PTPs been categorically established as negative
regulators of PTK signaling and paradoxically a number of PTPsmediate
positive roles in PTK-dependent signaling cascades likely through de-
phosphorylation of sites that serve in negative regulation of PTK signal-
ing [4]. Consistentwith this dual role, recent cancer genome sequencing
analyses have revealed that PTPs may function in both negatively (as
putative tumor suppressors) and positively (as oncogenes) regulating
oncogenesis [5].
2.3. Endocytic trafﬁc of protein tyrosine kinase-associated receptors as a
determinant of duration and diversiﬁcation of signaling
Similar to ligand-binding cell surface receptors in general, PTK-
associated receptors invariably undergo ligand-induced internalizationthrough the endocytic pathway (Fig. 1). The rapid relocation of activat-
ed receptors from the cell surface into endocytic compartments has
emerged as a fundamentalmechanism to control signaling downstream
of PTK-associated cell surface receptors. Studies over the last quarter
century have elegantly demonstrated that a major consequence of the
internalization of activated receptors is their trafﬁcking to lysosomes
where they undergo degradation [6,7]. This provides a mechanism of
signal termination that appears to be essential for regulating signaling
outputs from activated PTK-associated receptors under physiological
conditions. Indeed, endocytosis-impaired receptors, such as EGFR with
a deletion of its C-terminal sequences, become hyperactive and
transforming [8]. Similarly, higher signaling potency of ErbB2, com-
pared to its family members such as EGFR, has been attributed to its
being internalization (and lysosomal degradation)-impaired [9,10].
Further studies have demonstrated that lysosomal degradation is not
an invariant, or the only, consequence of the endocytosis of activated
PTK-associated receptors. For example, while studies of EGFR using its
prototypical ligand EGF have demonstrated lysosomal degradation as a
major consequence, TGFα stimulation is associated with less lysosomal
degradation of EGFR and a higher degree of its recycling back to the
cell surface [11,12]. More recent analyses of all available EGF ligands
have further established the distinct itineraries of internalized EGFR
depending on the ligand [13]. In other studies, it has been established
that concentrations of ligands can also dictate distinct itineraries of inter-
nalized receptors. For example, lower concentrations of EGF sufﬁcient for
induction of cell proliferation were associated with internalization of
EGFRbut not its degradationwhile higher concentrations of EGFpromot-
ed EGFR degradation [14]. These ﬁndings, together with studies of addi-
tional PTK-associated as well as non-PTK-associated receptors have
contributed to the idea of endosomal signaling [15,16].
According to this newer concept, internalization of activated
receptors by itself is not a signal attenuation mechanism. Instead,
internalized receptors continue to signal within endosomal compart-
ments until they are degraded in the lysosome or inactivated by other
mechanisms and returned to the cell surface. The extent of receptor
signaling within endosomes may indeed surpass that at the cell sur-
face. In all cell models, the life of an activated RTK on the cell surface
is very short (1–3 min) yet substantial degradation of internalized,
activated receptor typically takes ten times longer: thus, activated
RTKs spend nearly 90% of their lifespan within endosomes [6,7]. Stud-
ies in many cell systems have now shown that internalized RTKs
continue to signal [15,17,18]. For example, signaling proteins such as
Grb2 and Shc remain physically associated with activated EGFR and
NGF receptors even after they traverse to endosomes [17–19]. Signaling
from endosomes is indeed required for Trk receptor-mediated gene
regulation in the neuronal cell body in response to stimulation at distant
nerve endings [16].
Continued signaling ability of internalized PTK-associated receptors
therefore provides a potentialmechanism to regulate the duration of sig-
nal output depending on cellular needs. Thus, ligands (or concentrations
of ligands) that promote lysosomal degradation can be anticipated to in-
duce a relatively un-sustained signal output. In contrast, ligand condi-
tions that do not promote lysosomal degradation can be anticipated to
provide more sustained signaling outputs [6,7]. Studies of growth factor
receptors inmodel cell systems have demonstrated that the transient vs.
sustained activation of a single signaling axis can have dramatically dif-
ferent consequences for cell fate decisions. For instance, elegant studies
using PC12 neuroblastoma cells have shown that transient Erk activation
by EGF leads to a proliferative outcomewhile sustained Erk activation in
response to NGF is associated with neuronal differentiation [20]. In a
more recent example, maintenance of primary mammary epithelial
organoid cultures in EGF versus amphiregulin determined the domi-
nance of basal vs. luminal cell populations based on the extent of Erk
activation [21].
In addition to regulating the duration and intensity of signaling
outputs, evidence also supports the role of endosomal signaling by
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Fig. 1. Alternate routes of endocytic trafﬁc of activated tyrosine kinase coupled cell surface receptors and the role of Cbl-family protein dependent ubiquitination. The schematic
shows the EGF-induced activation and endocytosis of EGF receptor (EGFR) as a prototype; for simplicity, only clathrin-dependent endocytic pathway is shown. EGF activation
leads to receptor dimerization, auto-/trans-phosphorylation and recruitment of signaling proteins including Cbl proteins. The activated receptors accumulate in clathrin-coated
pits followed by internalization into early endosomes (EE) and trafﬁc to sorting endosomes (SE), late endosome/multi-vesicular body (MVB) and ﬁnally lysosomes (degradative
pathway). Alternatively, internalized receptors can be sorted into recycling pathway and returned for further ligand binding and activation (Recycling Pathway). Cbl-dependent
ubiquitination is thought to serve as an internalization signal and as a sorting signal at the level of MVBs. The latter role involves the recognition of the ubiquitin modiﬁcation
on the receptor by components of the ESCRT complexes to facilitate the sorting of ubiquitinated receptors into internal vesicles of the MVB, an event required for lysosomal deg-
radation of activated receptors. Non-ubiquitinated receptors or those fromwhich ubiquitin species have been removed by deubiquitinases (DUBs) are thought to enter the recycling
pathway. Signaling proteins that interact with Cbl proteins and are ubiquitinated may also be targeted for an alternate mode of degradation in the proteasome.
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tion of EGFR endocytosis with a dynamin-K44A mutant reduced the
level of phosphorylation of EGFR, the p85 subunit of PI3-kinase and
Erk1, but increased the phosphorylation of PLCγ1 and Shc [22]. Recent
studies indicate that RTK internalization is required for full MAPK
activation, apparently due to the localization of a critical MEK-MAPK
tethering protein within endosomes [23,24]. Additional studies have
uncovered endocytic pathways that deliver active receptor signaling
complexes to ER and Golgi for Ras activation [25]. Indeed, the require-
ment of endocytosis to activate signaling pathways extends to other
receptors, such as G-protein-coupled receptors and TGFβ receptor
[26–28]. Notably, endocytosis of EGF-EGFR complexes in the presence
of a washable tyrosine kinase inhibitor (TKI), followed by inhibitor
washout, demonstrated that initiation of signaling directly from
endosomes was sufﬁcient to promote cell survival and cell-cycle entry
[29,30]. The new paradigm of endosomal signaling by receptors activat-
ed by their ligands at the cell surface therefore provides a uniquemech-
anism for spatio-temporal regulation to achieve optimal duration and
diversiﬁcation of signaling outputs.
Given the vastly distinct functional consequences of endosomal
sorting of internalized PTK-associated receptors into alternative lyso-
somal vs. recycling fates, the regulatory mechanisms involved have
been of great interest. Early studies demonstrated that EGF-dependent
lysosomal targeting of EGFR was a saturable process, suggesting the
likelihood that certain key regulatory proteins were rate-limiting [31].
Recent studies have established that this postulated mechanism for
lysosomal sorting of activated PTK-associated cell surface receptors is
mediated by members of the Cbl family of ubiquitin ligases. The next
sections therefore focuses on a brief overview of the ubiquitin pathwayfollowed by a discussion of how the Cbl family of proteins controls lyso-
somal sorting of activated PTK-associated receptors to provide a funda-
mental mechanism of negative regulation of signaling. We will then
discuss the physiological implications of this mechanism and patholog-
ical consequences of its aberrations.3. Ubiquitin machinery and the control of cellular signaling by
protein tyrosine kinase-coupled cell surface receptors
3.1. Components of the ubiquitin pathway
The pathway of post-translational modiﬁcation of proteins with
ubiquitin involves a highly conserved enzymatic cascade [32–34]. A
ubiquitin-activating or E1 enzyme initiates the cascade in which a series
of enzymatic reactions lead to an ATP-dependent thioester bond
formation with the C-terminus of a ubiquitin molecule. This activated
E1-ubiquitin conjugate binds with high afﬁnity to a ubiquitin-
conjugating enzyme (UBC) and transfers active ubiquitin to E2, again
linked via a thioester bond. The E2 enzymes stably associate with
ubiquitin ligase enzymes (E3s) ofwhich the twomain classes are the cat-
alytic variety of HECT-domain containing E3s and the non-catalytic cate-
gory of RING ﬁnger domain (and related domains)-containing E3s. The
E2 enzymes bound toHECTdomain-containing E3s transfer the ubiquitin
moiety to E3 (via a thioester bond), which in turn transfers ubiquitin to
the ε-amine groups of lysine residues in target polypeptides through a
stable iso-peptide linkage. The E3s of the RING ﬁnger domain category
function as scaffolds, with the E3-bound E2 directly transferring ubiquitin
to the target.
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can be subjected to ubiquitin modiﬁcation relatively speciﬁcally
[32–34]. Only two ubiquitin-directed functional E1s exist in mammals
and it is likely that they function in distinct cellular processes, although
their redundant roles remain to be fully explored. There are nearly three
dozen E2s, a majority of them dedicated to the ubiquitin pathway. In
contrast, several hundred ubiquitin pathway E3 proteins are encoded
by the mammalian genome. The large number of E3s broadens the
range of target proteins that are regulated by ubiquitin modiﬁcation.
E3s typically use distinct domains/motifs (and often several of them)
to speciﬁcally interact with their substrates, with many of the interac-
tions involving recognition of motifs generated by post-translational
modiﬁcations (such as phosphorylation; this will be further illustrated
with the interactions of Cbl proteins below). These speciﬁc interactions
and their modulation under deﬁned physiological conditions provide a
mechanistic basis for ubiquitin modiﬁcation of a limited group of sub-
strates during speciﬁc cellular processes.
3.2. Types of ubiquitin modiﬁcation and their consequences
In general, the major categories of ubiquitin modiﬁcation of target
proteins involve mono-ubiquitination and poly-ubiquitination with
the latter involving chains linked through various lysine residues in
ubiquitin (e.g., commonly observed K48- or K63-linked chains) or
mixed chains [32–34]. While the precise regulatory mechanisms that
result in a particular type of ubiquitin modiﬁcation are not well
understood, the type of ubiquitin modiﬁcation dictates distinct func-
tional consequences for the modiﬁed proteins. The common form of
K48-linked poly-ubiquitin chains serves as a proteasomal targeting sig-
nal leading to degradation in the proteasome. In contrast, K63-linked
poly-ubiquitin chains do not appear to function in proteasomal
targeting. Both K63-linked chains as well as mono-ubiquitin modiﬁca-
tion, which is frequently seen in signal transduction, transcriptional
and other regulatory pathways, dictate protein–protein interactions
that do not lead to proteasomal degradation.
In the context of PTK-associated cell surface receptors, which is the
main focus of this review, the receptors themselves or their associated
adaptor proteins undergo K63-linked poly-ubiquitin and/or mono-
ubiquitin modiﬁcations [35]. These modiﬁcations are recognized by a
network of proteinswith ubiquitin binding domains. These interactions
provide a basis for recognition of ubiquitin-modiﬁed PTK-associated re-
ceptors by a series of multi-protein complexes referred to as the
Endosomal Sorting Complex Required for Transport (ESCRT). The serial
handover by ESCRT 0-III complexes is critical for sorting ubiquitin-
modiﬁed receptors on outer limiting membrane of the multi-vesicular
body (MVB) compartment of the endocytic pathway for delivery to
inner vesicles of this organelle. This step is critical for further transport
of receptors to the lysosome where they are degraded by lysosomal
hydrolases (Fig. 1).While a greater structural and functional complexity
is seenwith themammalian ESCRTmachinery, the components and the
architecture of ESCRT complexes is conserved from yeast to mammals.
The ESCRT machinery has been thoroughly reviewed elsewhere
[35–39], and will not be discussed in further detail here.
3.3. The role of the de-ubiquitination machinery
Over 100 proteases in the mammalian genome are members of
several subfamilies of de-ubiquitinases (DUBs). These enzymes playmul-
tiple roles in regulating the ubiquitination process.Members of this group
are essential for generating ubiquitin from its precursor covalent fusions
with itself or other polypeptides as well as in regenerating ubiquitin
from ubiquitin-modiﬁed proteins. Importantly, members of this enzyme
family are involved in proteasomal degradation of ubiquitinated proteins
as they play essential roles in processing and removing ubiquitin chains to
facilitate the entry of ubiquitin-targeted polypeptides into proteasomal
core, which harbors the catalytic proteases. Signiﬁcantly, emergingevidence indicates key, and seemingly opposite, roles of DUBs in regulat-
ing endocytic trafﬁc of PTK-associated receptors. Studies in yeast identi-
ﬁed an essential role of the de-ubiquitinase Doa4/Ubp4 in vacuolar
sorting of ubiquitinated receptors. Studies of the mammalian homolog
of this DUB, Usp8/UBPY, in the context of RTKs have produced somewhat
conﬂicting results. One set of studies indicates that Usp8/UBPY-mediated
de-ubiquitination reduces the lysosomal degradation of RTKs such as
EGFR [40]. Other studies have suggested an opposite role of facilitating
RTK degradation [41]. More in depth analyses have begun to shed light
on this complexity and apparently contradictory ﬁndings from different
studies. It has now become clear that Usp8/UBPY also regulates the level
of ubiquitination of other endocytic pathway regulators; such as the
components of the receptor internalization and ESCRT machinery and
alterations in Usp8/UBPY are associated with marked changes in the
structure of endocytic compartments [42]. Similarly, endosomal
deubiquitinase AMSH (Associated Molecule with the SH3-domain of
STAM) has been shown to antagonize the ubiquitin-dependent lysosomal
degradation of EGFR by trimming the K63-linked ubiquitin chains [43]
while other studies have shown this DUB to be required for MVB-
dependent EGFR degradation [43,44]. Furthermore, recent studies have
shown that Usp8/UBPY and AMSH may regulate each other [45] as well
as E3s such as the ErbB3-directed Nrdp1 [46]; therefore, their direct ver-
sus indirect effects require further elucidation. Notably, Usp8/UBPY is
transcriptionally up-regulated by PTK-coupled cytokine receptor activa-
tion and its inducible upregulationwas shown to alter colony stimulating
factor 3 receptor trafﬁc [47]. Thuswhile initial studies support a role of the
Usp8/UBPY and AMSH deubiquitinases in providing a layer of regulation
in the ubiquitin-dependent lysosomal sorting and degradation of activat-
ed PTK-associated receptors, the generality of this concept needs to be
established in the context of additional RTKs and the cellular and/or mo-
lecular contexts that lead to distinct outcomes of their DUB function in
RTK trafﬁc need to be delineated [48].
Further pointing to this complexity, ubiquitin speciﬁc protease 2a
(USP2a), a DUB that can remove both K48- and K63-linked poly-
ubiquitination chains from substrates, localizes at the early endosome
and exhibits oncogenic transforming activity, de-ubiquitinates and
stabilizes internalized EGFR and promotes its recycling back to the cell
surface [49]. Recently, the ovarian tumor protease DUB family member
Cezanne-I (also known as A20) was demonstrated to directly interact
with EGFR, induce de-ubiquitination of the receptor and curtail its
ligand-induced degradation; notably, Cezanne-1 was overexpressed in
breast cancer patients and its mRNA overexpression predicted aggres-
sive disease [50]. It is pertinent that Cezanne-1/A20 is an established
regulator of NF-κB signaling and other pathways [51], more in depth
analyses into its RTK regulatory function are warranted.
As the relative substrate selectivity and subcellular localization of
DUBs during dynamic cellular processes remain relatively poorly charac-
terized, further studies of their roles that reﬂect the regulation of the
endocytic itinerary of PTK-associated cell surface receptors versus other
functions are needed. The roles of DUBs demonstrated by these isolated
initial examples also highlight the need for more unbiased studies of the
larger DUB family. Such analyses should help uncover the potential roles
of DUBs in the endocytic trafﬁc of the wider group of PTK-associated re-
ceptors with attention to the tissue-speciﬁc and developmental patterns
of expression of DUBs as these become more clearly deﬁned, and may
help elucidate novel mechanisms of PTK mediated oncogenesis that
can be targeted for new therapeutic interventions.
3.4. Direct targeting of PTKs by the ubiquitin machinery
Following the well-established antagonistic relationship of phos-
phorylation and dephosphorylation as physiological switches, early
studies of PTK regulation naturally focused on phosphotyrosine phos-
phatases (PTPs). As indicated above, PTPs provide one mechanism for
negative regulation of PTK signaling although the vast majority of
PTPs appear to have complex roles, including positive roles in PTK
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other cellular PTKs have also shown these cellular signaling switches
to be potent proto-oncogenes whose oncogenic activity can be
unleashed by overexpression, mutational or heterologous fusion-
dependent activation, and other mechanisms [52]. Thus, it is not
surprising that ubiquitination, an ancient pathway of regulating
protein function, has evolved as an additional biochemical mecha-
nism of PTK regulation.
Although ligand-induced ubiquitination of a RTK, PDGFR, was
observed in early studies [53] the potential for PTK ubiquitination as
a regulatory mechanism became clearly established in the early to
mid-1990s through the convergence of a number of studies on the
proto-oncogene Cbl, which is the focus of this review and is discussed
in detail below.
The idea that direct interaction with Cbl or its family members
(below), targets PTKs for ubiquitination and that this has regulatory
consequences has led to considerable interest in other E3s with po-
tentially similar roles under distinct biological scenarios [32–34].
Numerous examples of E3s that may facilitate ubiquitin-dependent
regulation of PTKs are emerging and the list is likely to grow as
more comprehensive studies of the ubiquitome are undertaken. A
feature that sets the E3s of the Cbl family apart from all other E3sFig. 2. Evolutionary conservation of the primary structure and domain organization of Cbl prote
Cbl-b; and Cbl-c, Cbl-3 or Cbl- SL) as representative mammalian Cbl proteins; Chicken (Gallu
melanogaster) long and short Cbl; Worm (Caenorhabditis elegans) Cbl (SLI-1); and Dicty (Dictyo
Xenopus laevis, as Cbl sequences in the databases for the latter species were partial. Domain de
2; RF, RING Finger; L, Linker helical region; P, Proline-rich region; U, Ubiquitin-associated
and are shown as two values separated by “/” under % identity and similarity for whole protein
domains (TKB, Linker and RF). The latter emphasizes the higher evolutionary conservation of the
corresponds to amino acids 1-357 of mouse Cbl that are present in viral Cbl oncogene. Dicty Cbl
yasara.org); however, a linker helical region has not been identiﬁed in Dicty Cbl, making it an exclinked to PTK regulation is that they exclusively target PTKs and
selected PTK signaling components in a “PTK activation-dependent”
manner. The basis of this activated PTK-dependence involves mecha-
nisms that mediate the binding interactions of Cbl-family E3s as well
as the regulation of their activity by PTKs, as will be discussed below.
Thus, Cbl-family E3s serve a unique role as activation-induced feed-
back negative regulators of PTKs. The discussion below on the biolog-
ical consequences of genetic ablation of Cbl-family E3s together with
emerging evidence that their mutations lead to human disease
provide functional evidence that ubiquitination-dependent negative
feedback provides a layer of regulation of activated PTKs that is
distinct from the roles of PTPs and other mechanisms, and yet is
essential for physiological control of PTKs.
4. Cbl-family ubiquitin ligases
4.1. General structure of Cbl-family E3s
Cbl (Casitas B-lineage Lymphoma) protein is the founding mem-
ber of an evolutionarily-conserved family that includes three distinct
gene products (Cbl or c-Cbl; Cbl-b; and Cbl-c, Cbl-3 or Cbl-SL) in
mammals (Fig. 2). Cbl was initially isolated as the transformingins. The comparison includes: the three human (Homo sapiens) Cbl proteins (Cbl or c-Cbl;
s gallus) Cbl; Zebra ﬁsh (Danio rerio) Cbl; Frog (Xenopus tropicalis) Cbl; Fly (Drosophila
stelium discoideum) Cbl (Cbl-A). * Xenopus tropicalis was used for comparison rather than
signations: TKB, Tyrosine Kinase-Binding; 4H, four-helical bundle; SH2, Src-Homology
(UBA) domain; The amino acid sequences were compared to human Cbl and Cbl-b
(or available partial sequence; shown with // across C-terminal end) and for the N-terminal
N-terminal domains that constitute the core PTK-directed E3 activity of Cbl proteins. V-Cbl
4H region (inferred in UniProt) was conﬁrmed using the YASARA structure program (www.
eption in the entire Cbl protein family. N and C refer to amino and carboxyl termini.
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quent isolation of the cellular homologue of mouse Cbl demonstrated
that v-Cbl represents the truncated N-terminal part of Cbl fused to
viral Gag sequences; the Gag sequences, however, proved dispensable
for transformation of rodent ﬁbroblasts by v-Cbl [55].
Mammalian Cbl proteins fall into two distinct categories (Fig. 2): the
longer Cbl and Cbl-b gene products are highly related in their primary
structure as well as their domain architecture. In contrast, Cbl-c repre-
sents a shorter version that lacks some of the key C-terminal domains
and motifs. All three members of the Cbl family of proteins share a
highly homologous N-terminal region that serves as the structural plat-
form for direct binding to speciﬁc pY-containing peptide motifs in acti-
vated PTKs (Fig. 3) and is accordingly referred to as the Tyrosine
Kinase-Binding (TKB) domain; this domain is in fact a unique assembly
of a four-helical (4H) bundle, an EF hand domain and a variant SH2
domain, a tandem domain combination only found in Cbl-family pro-
teins [56]. The TKB domain is followed by a highly conserved helical
linker and a RING (Really Interesting New Gene) ﬁnger domain; these
two regions together form the structural platform for binding to a
ubiquitin conjugating enzyme (E2) [57] and this interaction is essential
for the E3 activity of Cbl proteins. The three N-terminal domains (TKB,
linker and RING ﬁnger) form the basic E3 module of Cbl proteins
(Fig. 4) and these domains are necessary aswell as sufﬁcient for activat-
ed PTK-directed E3 activity of Cbl [58,59].
Cbl and Cbl-b proteins contain additional C-terminal motifs/domains
known or presumed to mediate protein-protein interactions (Fig. 5)
[60–65]. These include: a proline-rich region that mediates interactionsCbl-TKB domain binding
 target Protein
Motif sequence relative
Group 1 Consensus seq
(D/N)XpY(S/T)
VEGFR-2 (human) YNSVVLpYST
EGFR (human) DSFLQRpYSS
PDGFR- ,  (human) ESIFDNLpYTT
Syk (human) TVSFNPpYEP
LET-23 (C. elegans ) SVNSSRpYKT
ZAP-70 (human) TLNSDGpYTP
Src/Fyn (Chicken) LIEDNEpYTA
CSF-1R (mouse) LLQPNNpYQ
Sprouty2 (human) TNEpYTEG
Group 2 Consensus seq
RA XNQpY(
APS (rat) RAVENQpYS
Group 3 Consensus seq
DpYR
MET (human) NESVDpYRA
Ron (human) YSGSDpYRS
Unassigned No consensus se
c-Kit (human) EEINGNpYVY
c-Kit (human) ESTNHIpYSN
Fig. 3. Phosphotyrosine-containing sequence motifs that mediate Cbl TKB domain binding t
critical amino acids that contribute to binding afﬁnity are indicated [208–210]. Φ indicatesof Cbl proteins with SH3 domain-containing proteins such as Src-
family kinases, Grb2, CIN-85 and others; several tyrosine residues
whose phosphorylation generates binding motifs for interaction with
SH2 domain-containing signaling proteins that form key intermediates
in PTK-dependent signaling networks, including Vav-family of guanine
nucleotide exchange factors (GEFs) for Rho-family GTPases (bind to
human Cbl Y700), p85 subunit of PI 3-kinase (binds to human Cbl
Y731) and Crk-family of adaptor proteins that link Cbl proteins to C3G,
a GEF for Ras-related small GTPase Rap1 (binds to human Cbl Y774).
The sequences near the C-terminus of Cbl and Cbl-b encode a leucine zip-
per (LZ)-like motif/Ubiquitin-Associated (UBA) domain that is known to
facilitate dimerization under certain experimental conditions [66]; this
region also functions as a ubiquitin-associated (UBA) domain capable
of binding to ubiquitin chains [67]. However, the functional roles of the
LZ/UBA domain remain unclear although its ability to mediate
ubiquitin-dependent dimerization has been suggested to provide a po-
tential mechanism of activation of Cbl proteins [68].
In contrast to Cbl and Cbl-b, Cbl-c lacksmost of the C-terminal regions
except for a short proline-rich region for potential interactions with SH3
domain-containing proteins. Cbl-c also lacks a LZ/UBA domain as well as
the region that harbors the tyrosine phosphorylation sites discussed
above.
4.2. Evolutionary conservation of Cbl-family
Cbl proteins homologous tomammalian Cbl proteins have been iden-
tiﬁed in non-mammalian species including model genetic organisms to consensus Residues! Reference
uence
XXP
PPI Tyr1052/1057 [208] 
DPT Tyr1045 [101] 
LSD Tyr1021 [82, 90] 
ELA Tyr323 [86] 
EPF Tyr1225 [84] 
EPA Tyr292 [56] 
RGQ Tyr416/
Tyr417
[209] 
FC Tyr973 [210] 
P Tyr55 [145] 
uence
S/T)
FY Tyr618 [109] 
uence
TFP Tyr1003 [108] 
GLA Tyr1017 [107] 
quence
IDP Tyr568 [110] 
LAN Tyr936 [110] 
o its targets. The consensus motifs and individual target protein sequence motifs with
hydrophobic residue. The motifs and sequences are adapted from [106].
Fig. 4. Domain architecture of Cbl proteins andmajor protein-protein interactions involving
various domains/motifs. The N-terminal Tyrosine Kinase-Binding (TKB) domain binds to
phosphotyrosine (pY)-containing sequence motifs in target proteins, that typically include
activated receptor and non-receptor tyrosinekinases. The Linker region and the RINGﬁnger
(RF) domain bind to ubiquitin conjugating enzymes (E2). Theproline-richmotifs (Pro-rich)
bind to SH3 domain containing signaling and endocytic proteins. Induced tyrosine
phosphorylation sites (major sites at Y700, Y731 and Y774 are shown) recruit SH2
domain-containing signaling proteins. The Ubiquitin-associated (UBA) domain/leucine
zipper near the C-terminus is involved in ubiquitin binding and dimerization. N and C
refer to amino and carboxyl termini.
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Dictyostelium (Fig. 2) [60–65]. These Cbl orthologs exhibit a domain
structure similar to that of mammalian Cbl-family proteins, with strik-
ing conservation of the domain architecture as well as the primary
sequences of critical N-terminal functional domains. For example, the
TKB, Linker and RING ﬁnger domains of the C. elegans Cbl ortholog
SLI-1 together exhibit 55% identity and 74% similarity at the amino
acid level with the corresponding regions of human Cbl (Fig. 2). The
evolutionary comparison also shows that the equivalents of both the
longer (Cbl and Cbl-b) and shorter (Cbl-c) Cbl-family proteins exist in
simpler organisms: for instance, the C. elegans Cbl (SLI-1) and the
shorter alternatively-spliced form of Cbl in Drosophila closely resemble
mammalian Cbl-c in their domain organizationwhile the domain struc-
ture of the longer form of Drosophila Cbl resembles that of mammalianFig. 5. Schematic representation of the basic role of Cbl-family proteins as ubiquitin ligases (E
a prototype of the family. The TKB domain, the proline-rich motifs and the induced tyrosine p
ubiquitin conjugating enzyme (E2) serves as an acceptor of activated ubiquitin from a ubiqu
of Cbl to promote mono-ubiquitination (shown as a single UB subunit) or poly-ubiquitinatCbl and Cbl-b [69,70]. The Cbl protein family has a relatively ancient
origin with an ortholog in Dictyostelium; the latter shows conservation
of the N-terminal regions that mediate phospho-tyrosine sequence-
dependent interaction of mammalian Cbl proteins with target proteins
(TKB domain) and E2 (RING ﬁnger). Notably, however, Dicty-Cbl does
not appear to have the helical linker region found between SH2 and
RING ﬁnger domains of all other Cbl proteins, and functions as a positive
regulator of signal transducer and activator of transcription (STAT) pro-
tein by binding to and down-regulating a phosphotyrosine phosphatase
PTP3 [71]. The conservation of domain architecture as well as the pri-
mary structure strongly suggest a conservation of the biological func-
tions as well the biochemical mechanisms by which Cbl proteins exert
their functional effects, as discussed below.4.3. Cbl-family proteins as “activated PTK-selective” E3s—evolution of the
concept
A number of key early observations contributed to the current
paradigm that Cbl-family E3s function as selective regulators of
activated PTKs in higher organisms. Identiﬁcation of the v-Cbl onco-
gene [54,72] implied that the N-terminal region of c-Cbl (which is in-
corporated in the oncogene) might interact with critical cellular
proteins to dominantly deregulate their function and unleash an on-
cogenic program. However, the nature of cellular machinery targeted
by Cbl remained unknown until multiple lines of evidence helped di-
rect attention to PTKs. Several independent studies in the mid-1990s,
investigating either Cbl or various PTKs, quickly converged to estab-
lish that Cbl is a direct binding partner and substrate of mammalian
non-receptor and receptor type PTKs. Notably, Cbl was found to be ty-
rosine phosphorylated in cells oncogenically transformed with v-Abl
indicating that Cbl is a substrate for a deregulated PTK [73]. This led
to further analyses in which Cbl was found to be tyrosine phosphory-
lated in response to T-cell receptor engagement in cell lines, indicat-
ing that Cbl was a substrate of physiological PTK machinery [74].
Independent studies identiﬁed a novel 120 kD cellular protein
(p120) that directly interacted with SH3 domains of T-cell receptor-
associated Src-family kinases Fyn and Lck andwas rapidly tyrosine phos-
phorylated upon T-cell receptor stimulation [75]. Subsequent puriﬁcation
of p120 identiﬁed it as Cbl [76]. Additional studies showed that stimula-
tion through T-cell receptor as well as related B cell antigen receptor led
to tyrosine phosphorylation of Cbl and its complex formationwith down-
stream signaling proteins including Grb2, PI3-kinase p85 subunit, and Crk
adaptor proteins [60,77–79]. Other studies quickly established tyrosine
phosphorylation as well as signaling protein complexes of Cbl upon
stimulation of EGFR in multiple cell systems [73–75,80–83]. In parallel,
genetic screens in C. elegans identiﬁed the worm ortholog of Cbl (SLI-1)
as a negative regulator of EGFR (LET23)-mediated vulva development3s) towards components of tyrosine kinase signaling pathways. Human Cbl is shown as
hosphorylation sites recruit targets for ubiquitin modiﬁcation. The linker/RF-associated
itin-activating enzyme (E1) and transfers it to targets bound to various domain/motifs
ion (shown as four UB subunits).
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amino acid missense mutation (G to E; equivalent to human Cbl
G306) within the evolutionarily-conserved region preserved in
v-Cbl [84]. Collectively, these advances suggested a critical role of
the conserved N-terminal region of Cbl in its function with the possi-
bility that this region may be related to the interaction of Cbl with
PTKs.
Direct binding assays using puriﬁed recombinant Cbl fragments
incorporating the N-terminal region of Cbl, corresponding to v-Cbl
sequences (Cbl amino acids 1–357; also referred to as Cbl-N), allowed
a test of this hypothesis. GST-Cbl-N selectively and directly bound to
phosphorylated ZAP70 tyrosine kinase in an activated T cell line and to
related PTK Syk in an activated B lymphocyte line [85,86]. From screen-
ing of oriented phosphopeptide libraries and mutagenesis, it was
established that Cbl-N bound to the negative regulatory pY-containing
peptide motifs within the linker region of ZAP70 and Syk [87] (Fig. 3).
Importantly, a point mutation (human Cbl-G306E) corresponding to
the loss of function allele of C. elegans SLI-1 completely abrogated the
ability of the TKB domain to interact with pY-peptidemotifs on activated
PTKs thereby linking the genetically identiﬁed loss of Cbl's function as a
negative regulator in C. eleganswith PTK-binding activity in mammalian
cells. Similar pY-containingmotifs that allow direct binding on activated
PTKs have been identiﬁed on other PTKs (Fig. 3) (hence the designation
Tyrosine Kinase-Binding or TKB domain) [60,85].
The idea of a TKB domain-mediated regulatory interaction of Cbl
with activated PTKs was further supported by observations in ﬁbro-
blasts which showed that the overexpression of oncogenic mutants of
Cbl hyper-activated while the overexpression of wild-type Cbl reduced
the level of PDGFR signaling in a manner that required an intact TKB
domain [82,88]. Studies of ﬁbroblasts overexpressing human EGFR
showed that transforming Cbl mutant expression was associated with
increased EGFR phosphorylation [89]. Biochemical studies in ﬁbroblasts
with or without Cbl overexpression demonstrated that Cbl-dependent
negative regulation of PDGF receptor was a consequence of its Cbl-
dependent ubiquitination which was associated with an enhancement
of the ligand-induced down-regulation of the receptor from the cell sur-
face [88,90]. Parallel studies demonstrated the facilitation by Cbl of
EGF-induced down-regulation of EGFR and further demonstrated this
to be due to enhanced lysosomal trafﬁc of the internalized EGFR [59].
These ﬁndings led to the idea that Cbl-dependent ubiquitination of
RTKs, such as PDGFR and EGFR, facilitates their internalization and/or
lysosomal sorting akin to a model based on genetic and biochemical
studies of yeast G-protein coupled pheromone receptors [91,92]. In-
deed, these analyses were extended to hepatocyte growth factor recep-
tor c-MET andmutation of Cbl binding site of c-MET led to its acquiring
oncogenic trait [93]. Furthermore, ubiquitination and downregulation
of cell surface M-CSF receptor on bone marrow macrophages was re-
duced in Cbl-null mice [94]. [94,94,95] Further studies with a number
of non-receptor PTKs such as Fyn, Lck, Src, ZAP-70 and Syk that are as-
sociated with other cell surface receptors [58,96–99] helped establish
the generality of Cbl-dependent ubiquitination of activated PTKs.
The ability of Cbl to induce PTK ubiquitination and the presence of
a highly conserved RING ﬁnger domain (shown in other proteins to
bind to E2) adjacent to the TKB domain prompted in vitro biochemi-
cal analyses that established that Cbl functions as an E3 towards an
activated PDGF receptor; the TKB domain was needed to contact the
substrate and the RING ﬁnger was shown to recruit E2 [100]. Analyses
of truncation and point mutants of Cbl in the context of Syk/ZAP70
and EGFR demonstrated that the TKB and RING ﬁnger domains were
necessary as well as sufﬁcient for PTK ubiquitination and degradation
[58,59,99,101]. Subsequent studies established the E3 function of
Cbl-b and Cbl-c and demonstrated that their TKB and RING ﬁnger do-
mains were required for their E3 ligase activity [102–105]. Altogether,
these studies helped establish that the core function of Cbl-family
proteins is to link the ubiquitin machinery to negative regulation of
activated PTKs.4.4. Structural basis for activated PTK-selectivity of E3 function of Cbl
proteins
The evolutionarily-conserved N-terminal region forms the core E3
module of Cbl-family proteins (Fig. 4). The TKB domain binds to speciﬁc
phosphotyrosine-containing sequence motifs that are generated on
PTKs upon their activation. Several ﬂavors of these motifs have now
been identiﬁed on known targets of Cbl proteins with different N and
C-terminal residues relative to phosphotyrosine contributing to the
afﬁnity and speciﬁcity of binding (Fig. 5). A relatively common and
high afﬁnity motif is found on the Cbl TKB domain-binding site on
ZAP70 ((D/N)XpY(S/T)XXP, initially identiﬁed based on the Cbl TKB do-
mainmotif selection in a phospho-peptide library screen and further re-
ﬁned through experimental studies [56,85–87,101,106]. A DpYR-based
motif is found on c-MET and several other RTKs [107,108]. Finally,
RAФXNQpY(S/T)-related motifs are found in APS-related adaptor pro-
teins that link Cbl to several cell surface receptor targets that lack direct
TKB domain-binding motifs, such as the insulin receptor (Fig. 2)[109].
Furthermore certain RTKs such as c-kit use non-consensus TKB domain
binding motifs to interact with Cbl [110]. It remains possible that other
Cbl TKB domain-binding pY-bearing motifs will be uncovered as analy-
ses of Cbl-interactome are expanded.
The second highly-conserved N-terminal domain that is an essen-
tial component of the basic E3 ubiquitin ligase function of Cbl pro-
teins is the RING ﬁnger domain along with the helical linker region
that connects it with the TKB domain. Together, these domains
provide an interface for binding to E2s and thus help juxtapose the
TKB domain-bound target PTKs with E2s, enabling their ubiquitin
modiﬁcation. Structural studies and mutational analyses clearly
demonstrated that both the RING ﬁnger and helical region are re-
quired for E2 binding and ubiquitin ligase activity of Cbl towards
PTKs [58,105,111–114]. Initial structural studies indicated that PTK
targets (mimicked using the phospho-peptide motif from ZAP70)
and E2 would lie on different sides of the TKB domain and hence
did not clarify how the RING ﬁnger bound E2 would be positioned
close to target PTKs to mediate ubiquitination [111]. Two lines of ev-
idence however suggested a potential phosphorylation-dependent
switch. First, the kinase activity of the target PTKs was found to be
necessary for Cbl-dependent ubiquitination [115,116]. While the
requirement of the kinase activity could reﬂect the need to generate
a Cbl TKB domain-binding motif on RTKs or adaptor proteins, we
showed that the Cbl TKB domain-mediated binding was dispensable
yet the kinase activity was required for ubiquitination of the
Src-family kinase Fyn [73,116]. Further studies revealed that target
PTKs promote the phosphorylation of a conserved tyrosine residue
in the helical linker of Cbl (human Cbl Y371) whose Y–F mutation
leads to loss of E3 function [117]. Recent crystal structural analyses
of the TKB, helical and RF domains in un-phosphorylated versus
Y371 phosphorylated states provided evidence that phosphorylation
of Y371 reorients the helical region resulting in increased E2 binding
and positioning of E2 closer to the phospho-peptide binding pocket of
the TKB domain [105,113,114]. Thus, binding to target PTKs is
thought to promote a linker phosphorylation-dependent activation
of Cbl E3 activity. While the recent structural studies investigated
this in the context of a TKB domain-bound PTK target, it remains
unclear if a similar mechanism might account for requirement of
the kinase activity for ubiquitination of targets recruited via domains
others than the TKB domain (as with SFKs and SH2 domain-
containing proteins; see below). It is also not clear if Y371 in Cbl is di-
rectly phosphorylated by the TKB domain-associated PTKs or by
secondarily-activated PTKs such as Src-family kinases. In this regard,
it is notable that Cbl-mediated ubiquitination and down-regulation
of PDGFR-αwas impaired if Src-association sites on PDGFR were mu-
tated or in cells lacking SFKs [118].
Once bound to target PTKs, Cbl and Cbl-b proteins also undergo
phosphorylation on several tyrosine residues located within the
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binding sites for SH2 domain-containing signaling proteins (discussed
above). It is noteworthy that the signaling proteins that form complexes
with Cbl proteins through SH2–phosphopeptide interactions (hence
PTK activity-dependent associations) also undergo Cbl-family E3-
dependent ubiquitination; this has been clearly demonstrated for
PI3-kinase, whose p85 subunit interacts with pY731 of Cbl [119], for
Vav and Vav2 [120,121] which interacts with Cbl pY700, and Crk/
CrkL-associated C3G protein, a guanine nucleotide exchanger for Rap
GTPases that interacts with Cbl pY774 [122]. Since structural studies
have not included the C-terminal region of Cbl or Cbl-b, it is at present
unknown what mechanisms might juxtapose signaling proteins
bound to these sequences with the RING ﬁnger domain-bound E2. The
C-terminal sequences and their phosphorylation (and interactions
with SH2 domain-containing proteins) however do not appear to be re-
quired for ubiquitination of TKB domain-bound targets as suggested by
the functionality ofmammalianCbl-c and that ofC. elegans SLI-1 and the
shorter isoform of Cbl in Drosophila as well as studies with truncated
Cbl proteins (discussed above).
4.5. Nature and consequences of Cbl E3-dependent ubiquitin modiﬁcation
of activated PTKs
In general, Cbl E3s facilitate mono- or poly-ubiquitination of the as-
sociated targets [112,123–128]. Cbl-dependent mono-ubiquitination
and K63-linked poly-ubiquitination appears to be a feature of activated
RTKs [112,124–128] while other targets, such as ZAP70/Syk and
Src-family kinases, appear to undergo poly-ubiquitination [60,97–99].
Notably, in most cases, these distinct modiﬁcations dictate degradation
of ubiquitinated targets of Cbl proteins but through distinct pathways:
mono- or K63-linked poly-ubiquitination of activated cell surface re-
ceptors facilitates their sorting to the lysosomes, based on recognition
of the ubiquitin chains by the Endosomal Sorting Complex for Transport
(ESCRT) machinery which facilitates the entry of ubiquitin-tagged re-
ceptors into inner vesicles of the multi-vesicular body (MVB) compart-
ment (see above) (Fig. 1); in contrast, many poly-ubiquitinated targets
of Cbl proteins appear to undergo proteasomal degradation [35–39].
However, in some instances, cytoplasmic signaling proteins associated
with activated RTK complexes may indeed be sorted together with
RTKs into the MVB and thereby undergo lysosomal degradation
[126,129]. Interestingly, degradation-independent negative regulation
by Cbl proteins has been suggested in selected cases. For example, neg-
ative regulation of PI3-kinase in T cells by Cbl-b was associated with
ubiquitination but not degradation, leading to the authors' suggestion
that Cbl-family E3 dependent ubiquitinationmaymediate negative reg-
ulation of PI3-kinase and potentially other targets by regulating subcel-
lular localization [119].
5. Functional roles of Cbl-family proteins
5.1. Functional roles of Cbl-family proteins based on evidence from in
vitro model systems
A large body of literature now documents the functional conse-
quences of the negative regulatory role of Cbl proteins using cellular
systems. As these have been reviewed in detail over the past several
years [63,77,78,130,131], this section will provide an overview of
the message that has emerged out of these studies.
As PTKs generally serve as membrane proximal switches to convert
extracellular signals into intracellular functional programs, the vast
majority of in vitro studies have naturally focused on the role of Cbl
proteins at the level of receptors themselves and at the level of proximal
signaling events downstream of PTK-associated receptors. As stated
above, the E3 activity of Cbl proteins plays a key role in the ubiquitination
of RTKs as well as receptors (such as antigen receptors on immune cells)
that are non-covalently linked to PTKs. There is general agreement thatthe overall consequence of Cbl-family protein-dependent ubiquitin
modiﬁcation of cell surface receptors is an enhancement of their lyso-
somal degradation via ESCRT protein-dependent facilitation of sorting
at the MVB compartment [7,63,129,132]. Another proposed mechanism
of the regulation of endocytic trafﬁc of PTK-associated surface receptors
by Cbl proteins, however, remains controversial. A series of investiga-
tions in the context of RTKs such as EGFR and c-MET, have indicated
that Cbl proteins facilitate RTK internalization from the cell surface
through a mechanism that may be independent of their E3 activity
[133,134]. The model emanating from these studies suggests that Cbl
proteins associate with activated RTKs via their TKB domains and recruit
the Cbl proline-rich region-associated SH3 domain-containing proteins
of the CIN85 family. CIN85 forms a complex with endophilin A, which
is known to be important in receptor internalization. Thus, Cbl-family
proteins are proposed to function as adapters to promote the internaliza-
tion of activated RTKs from the cell surface into early endocytic vesicles
(Fig. 1). Studies using mutant proteins in transfection studies support
this model [133]. Studies in other systems, however, have suggested
that Cbl proteins are dispensable for initial internalization of activated
RTKs and are essential only for the later step of lysosomal sorting. A rath-
er physiological approach using mouse embryonic ﬁbroblasts with com-
plete deletion of Cbl showed that initial internalization of activated EGFR
was not materially impaired [135] and our initial ﬁndings using Cbl plus
Cbl-b double knockout cells further support these conclusions
(unpublished observations). Consistent with these ﬁndings, EGFR was
shown to become internalized in a Cbl-independentmanner in response
to oxidative stress resulting in EGFR recycling rather than degradation
[136]. In addition, EGFR mutants defective in Cbl binding as well as
ubiquitin modiﬁcation are still internalized [137,138]. Thus, while it is
possible that Cbl proteins can facilitate receptor internalization this func-
tionmay be easily compensated for in the absence of Cbl protein recruit-
ment. However, Cbl proteins are essential for sorting of the internalized
PTK-associated receptors to the lysosome (Fig. 1). Further analyses are
needed to fully elucidate the relative importance of Cbl proteinsworking
through an adaptermechanismversus E3 activity, at two distinct steps in
the endocytic trafﬁc of PTK-associated cell surface receptors.
The second aspect of the functional roles of Cbl-family proteins
that has been elucidated through cellular studies relates to their
importance in regulating early biochemical pathways activated by
PTK-associated receptor signaling. Thus, in a range of cellular models
ranging from transfection analyses, knockdown analyses or cells
derived from mice with deletion of Cbl or Cbl-b studies have shown
that Cbl proteins negatively regulate the signaling outputs from acti-
vated PTKs into major downstream pathways such as the Ras-Erk,
PI3-kinase-AKT and STAT pathways [139–143] In general, loss of Cbl
protein-dependent negative regulation kinetically prolongs the acti-
vation of these signaling pathways upon receptor stimulation. These
effects are likely to be a result of the overall down-regulation of acti-
vated receptors through lysosomal degradation (which terminates
their ability to continue to signal), targeting of associated PTKs
(such as Src-family kinases, ZAP70/Syk) for proteasomal degradation,
and the ubiquitination of signaling proteins themselves if these are
able to interact with Cbl proteins directly. The latter mechanism ap-
pears to contribute to the negative regulation of PI3-kinase-AKT (via
p85 subunit interaction with pY731 of Cbl), Erk (via interaction of
Rap-GEF C3G with Cbl via Crk adaptors; possibly also via interactions
with sprouty proteins), and Rho GTPase family (via interaction with
GEFs of the Vav family) [97,99,115,120,121,140,144–147]. Other sig-
naling pathways are often impacted in speciﬁc cell types.
How the regulation of PTK-associated receptor trafﬁc and immedi-
ate biochemical pathways translate into speciﬁc biological responses
is however poorly understood. Perhaps the best links in this regard
have been established in speciﬁc immune system cellular studies. It is
clear, for example, that Cbl proteins regulate the actin cytoskeletal re-
modeling in T-cells that in turn is required for the stability of the immu-
nological synapse; as a result, Cbl-b deﬁcient T cells have longer lived
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resistant to induction of anergy [149]. Loss of Cbl-b or Cbl plus Cbl-b
in mice renders T-cells hypersensitive to T cell receptor activation for
cell proliferation and cytokine secretion and removes the requirement
for co-stimulatory signals normally delivered through CD28 or related
proteins [150]. However, the linkage of these functional effects with
speciﬁc biochemical pathways and regulation of T cell receptor
endocytic trafﬁcking remains poorly explored. How receptor proximal
events regulated by Cbl proteins translate into distal functional conse-
quences of PTK-associated receptor activation in other cell systems is
even less clear. For example, even though RTKs such as EGFR, PDGFR
and c-MET have been extensively analyzed with respect to receptor
trafﬁcking events and early biochemical responses regulated byCbl pro-
teins, how the physiological responses mediated by these receptors are
regulated by Cbl proteins remains to be fully examined. One trait often
altered in cells lacking Cbl proteins is cell migration response to growth
factors such as EGF or HGF; for example, EGF or HGF-inducedmigration
was increased in human mammary epithelial cells with Cbl plus Cbl-b
knockdown yet their EGF-driven proliferation was unaffected [121]. In
contrast, cytokine-induced proliferation of Cbl-null or Cbl plus Cbl-
b-null hematopoietic stem and progenitor cells is markedly enhanced
[151–153]. Little is known about how Cbl proteins might inﬂuence
distal transcriptional events, cell proliferation and differentiation
responses. These analyses are of fundamental importance to our under-
standing of the basis of physiological and pathological roles of Cbl pro-
teins emerging from animal models and human diseases (see below).
While the focus of the current review is on the role(s) of
Cbl-family E3s, it will be important for future studies to consider
their roles in the context of other negative regulatory pathways that
cells utilize to attenuate PTK-coupled receptor signaling. Apart from
Cbl-family E3s other ubiquitin ligases have emerged as negative reg-
ulators of PTK-coupled receptor by impinging on pathways similar to
those controlled by Cbl-family proteins; for example, Nedd proteins,
ITCH, Nrdp1, CHIP, Cullin-5 and SIAH proteins have been shown to
play a role in the ubiquitination and downregulation of PTK-coupled
receptors [63,154–156]. Consistent with ﬁndings from earlier genetic
studies in model organisms, recent analyses in mammalian systems
have also revealed an important additional layer of negative feedback
regulators that are induced upon receptor activation: examples of
such inducible feedback inhibitors include LRIG1 (leucine rich repeats
and immunoglobulin-like domain 1), suppressor of cytokine signaling
4 and 5 (SOCS4 and SOCS5) and receptor-associated late transducer
(RALT, also known as MIG6 and ERRF11) [155]. LRIG1, a cell surface
trans-membrane protein containing leucine-rich repeat domain and
three Ig-like modules interacts with extracellular region of EGFR in
a ligand independent fashion [157]. LRIG1 accelerates ligand induced
ubiquitination and degradation of EGFR. RALT, a cytosolic protein
with ErbB binding region (EBR) is recruited to the EGFR-kinase do-
main in a ligand-dependent fashion. Recruitment of RALT results in
catalytic inactivation of the kinase domain and abrogation of down-
stream signaling [158]. RALT also binds to AP-2 and intersectins and
promotes clathrin-dependent endocytosis [159]. Notably, RALT regu-
lates receptors at multiple points during their endocytic trafﬁc [160].
MIG6/RALT was recently implicated in promoting loss of cell survival
under conditions of growth factor deprivation [158]. While SOCS pro-
teins were initially characterized as inducible negative regulators of
cytokine receptors as elongin-dependent E3s, recent studies show
that SOCS4 and 5 bind EGFR in ligand-independent fashion through
their N-terminal and SH2 domains [161,162] and mediate an together
with elongin BC mediate EGFR downregulation [162].
These examples highlight the need for systematic studies to exam-
ine how Cbl-family E3s and other negative regulatory pathways func-
tion together to coordinate spatio-temporal regulation of PTK-coupled
receptor signaling that is critical for speciﬁcation of the nature and ex-
tent of cellular responses. Similarly, since Cbl-family proteins interact
with their target PTKs in a phosphotyrosine-dependent manner, thepotential role of phosphotyrosine phosphatases (PTPs) in regulating
Cbl-family E3-dependent negative regulation of PTKs needs to be clari-
ﬁed. For example, a Cbl/SHP2 complex has been implicated in the
ubiquitination and lysosomal degradation of gp130 receptor chain
upon IL-6 stimulation [163]. Conversely, an siRNA screen of PTPs for
dephosphorylation of EGFR identiﬁed density-enhanced phosphatase-
1 (DEP-1) and tumor suppressor as an EGFR-targeting PTP; DEP-1-
dependent dephosphorylation led to stabilization of EGFR by hamper-
ing its ability to associate with the CBL–GRB2 complex [164].
Negative regulation by Cbl-family E3s will undoubtedly function in
the context of other negatively regulators of PTK-associated receptors
thatmay function bymechanisms distinct fromubiquitin-dependent reg-
ulation. One family of such regulators that has received considerable at-
tention is that mediated by Sprouty proteins as these proteins have
been shown to directly associatewith Cblwith dramatic functional conse-
quences that appear to varywith the experimental systems [165]. Sprouty
proteins are inducible feedback negative regulators of PTK-coupled recep-
tor signaling that appear to primarily impinge on the Ras-Raf-Erk1/2
pathway [166,167]. Sprouty proteins have been shown to directly interact
with Cbl proteins via two potentially cooperative interactions. The
N-terminal region corresponding to residues 11–53 of human Sprouty 2
directly binds to RF domain of Cbl [168]. Stimulation of RTKs, such as
EGFR or FGFR, also promotes tyrosine phosphorylation of Sprouty pro-
teins on a tyrosine residue (tyrosine 55 on Sprouty 2; this residue is con-
served in all familymembers and in other species) that serves as a binding
site for Cbl TKB domain [145]. Analyses of RTKs such as EGFR, using in
vitro cell culture systems, have shown that Cbl-Sprouty association
sequesters Cbl from activated RTKs resulting in their inefﬁcient
ubiquitination and downregulation with a consequent increase in down-
stream signaling. Thus, this complex interaction appears to utilize a
known negative regulator of RTKs (Sprouty) to abrogate the effects of an-
other negative regulator (Cbl) effectively converting Sprouty into a posi-
tive regulator of RTK signaling [145]. Further analyses indicate that Cbl
TKB-Sprouty 2 pY55 interaction is required for the negative regulatory
function of Sprouty 2 towards Ras-Erk1/2 signaling [145,166]. In addition,
this interaction has been shown to promote the ubiquitination anddegra-
dation of Sprouty 2 [169]. Finally, other studies have noted a biphasic reg-
ulation with positive as well as negative regulatory roles of Cbl-Sprouty
complex that may inﬂuence RTK signaling in a spatio-temporal manner
[170,171]. Notably, induction of Sprouty 1 upon activation of CD4+ T
cells resulted in inhibition or enhancement of receptor signals depending
on the differentiation state of cells, suggesting that Cbl and Sprouty pro-
teins may function as a context-dependent regulatory complex for more
precise and versatile regulation of receptor signals during development
and tissue homeostasis [172]. Importantly, further studies, including in
vivo analyses, of the relative importance of Cbl proteins versus other neg-
ative regulators and their cross-talk should provide fruitful avenues to
elucidate the regulatory mechanisms that control biological processes
mediated by PTK-associated receptor signaling.
5.2. Functional roles of Cbl-family proteins based on evidence from in
vivo studies
5.2.1. Studies in model organisms
An early indication of a negative regulatory role of a Cbl-family
protein for a PTK-associated receptor came from studies in C. elegans
when a genetically identiﬁed negative regulator of the EGFR homolog
LET23 was identiﬁed as the worm Cbl (SLI-1) [84] (Table 1). Drosoph-
ila Cbl homolog has similarly emerged as a negative regulator of EGFR
signaling during photoreceptor development [173]. Drosophila Cbl is
also required for dorso-ventral patterning and germ cell migration
and functions by regulating RTK endocytic trafﬁc [174]. More recent-
ly, a Cbl ortholog in zebraﬁsh was shown to negatively regulate FGF8
signaling during embryonic development [175]. The mechanism and
consequences of the regulatory role of Cbl identiﬁed in these studies
are quite interesting with potentially important implications for
Table 1
In vivo roles of Cbl family genes revealed by genetic mutation and deletion approaches.
Organism (Gene) Mutation /Knockout (KO) Phenotype References
C. elegans (Sli-1) Loss of function mutation No phenotype in wildtype worms; Restoration of vulva
development defects inworms expressing a hypomorphic EGFR
(let-23) allele
[84]
Drosophila
(D-Cbl)
Transgene overexpression No phenotype in wildtype ﬂies; expression in a sensitized
background (expressing a disabled Sevenless kinase, SevE4)
eliminated photoreceptor R7 differentiation.
[173]
Loss of function mutation of D-Cbl Defective dorso-ventral patterning during oogenesis, ovarian
development and embryonic development. Disruption of the
wing development.
[174]
Ring ﬁnger mutant of D-Cbl (mutation of Cys-369,
corresponds to Cys-381 in human Cbl): affects both
D-CblL and D-CblS
Abrogated border cell migration during oogenesis. [211]
Deletion mutation (identical to loss of function
mutant of Schupbach group) and Ring ﬁnger
mutation of D-Cbl (mutation at Arg-406): affects
both D-CblL and D-CblS
Abnormal eye development, increased omatidial spacing and
larger head.
[212]
Zebra ﬁsh
(Cbl)
Y->F mutation in linker region Tyr-352 and 355
(corresponding to Tyr-368 and 381 of human Cbl)
Mutant ﬁsh show patterning defects during embryonic
development due to alterations of fgf8 (ﬁbroblast growth factor
8) morphogen gradient.
[175]
Mouse
(Cbl)
Complete (germline) Knockout (Cbltm1Ddlb) Hyperplasia of lymphoid organs, splenomegaly, increased
mammary gland branching.
[176]
Cbl−/− mice exhibited upregulated glucose metabolism, lean
muscles and low fat deposition in the body despite
hyperphagia, increased whole-body insulin action and energy
expenditure.
[179]
Complete (germline) knockout (Cbltm1.1Hua) Mice are born healthy and fertile. Mild splenomegaly due to
erythroid hyperplasia. Loss of Cbl in these mice altered thymic
positive selection by enhancing CD4 lineage Tcells.
[177]
Cbl knockout male mice are hypofertile. Absence of Cbl in the
testicular gonadal cells results in failure to induce apoptosis
during spermatogenesis.
[178]
Cbl-deﬁcient mice exhibit expansion of hematopoietic stem/
progenitor (HSC) pool in the bone marrow.
[151]
Mouse
Cbl-b
Knockout
(Cblbtm1Pngr)
Born at expected Mendelian ratios and fertile. At the age of
6 month display hugemass of salivary gland due to accumulation
of T cells andB-cells, and lymphoidneoorganogenesis inmost vital
organs of the body. Generalized spontaneous autoimmune
disorder around 6 months of age due to hyperactivation of
autoreactive T and B-cells. Older mice developed progressive
changes in facial features and enhanced osteoclastogenesis.
[180].
CD40-induced B-cell proliferation is enhanced in mutant
mice. Furthermore, Cbl-b−/− mice display enhanced
thymus-dependent antibody responses and germinal center
formation.
[213]
Knockout
(Cblbtm1Hua)
Mutant mice are fertile and grossly normal levels of T-, B-
and Natural Killer cells in peripheral and central lymphoid
organs. Mice more susceptible to induced experimental
autoimmune encephalomyelitis. Deﬁciency of Cbl-b leads to
loss of requirement for CD28 co-stimulation for T-cell
activation.
[181]
Mice showed symptoms of Type-2 diabetes by manifesting
glucose intolerance and insulin resistance around 20 weeks of
age. Inﬁltration of activatedmacrophages seen in white adipose
tissue.
[214]
Cbl-b-deﬁcient mice are resistant to unloading-induced
muscle atrophy and loss of muscle function as a result of
reduced IRS-1 (insulin receptor substrate-1) degradation.
[182]
Mouse
Cbl-c
Knockout
Cblctm1Pngr
No gross or micro-anatomic phenotype [183]
Mouse
Cbl and Cbl-b
Complete double Knockout Embryonic lethal by day E10. [150]
Conditional deletion in T-Cells
using Lck-Cre (on Cbl-b KO background)
Severe vascular lesions, lymphadenopathy, splenomegaly,
extramedulary hematopoiesis and symptoms of autoimmune
diseases. Impaired T-cell receptor down modulation. Mutant
mice exhibited disease sign after 3 weeks. Females became
moribund at 12 weeks, male mice by 16 weeks.
[150]
Conditional deletion in B-cells using CD19-Cre
(on Cbl-b KO background)
Mice develop spontaneous SLE-like autoimmune diseases.
Impaired B-cell intrinsic tolerance induction, Bcell and in-
duction of B-cell anergy. Half of the mutant mice became
moribund by 10 months of age.
[185]
Conditional deletion in HSC as a result of
MMTV-Cre
induced deletion of ﬂoxed Cbl (on Cbl-b KO
background);
expected Cbl deletion in mammary gland.
Mutant mice born at sub-Mendelian ratios. Mice develop severe
myeloproliferative disorders (MPD) by 5 weeks of age with a
median survival of 67 days.
[153]
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Table 1 (continued)
Organism (Gene) Mutation /Knockout (KO) Phenotype References
Mouse
Cbl-c
MMTV-Transgenic overexpression of Cbl-c in
mammary epithelium.
Retardation in mammary ductal branching. [215]
Mouse
Cbl (G304E)
Knock in
Cbltm1Wlan
No gross abnormality in organs and tissues except for mild
splenomegaly and dilated uterine horns and fallopian tubes in
mice of 6 to 9 weeks old.
[216]
Mouse
CblA/− (C379A)
Knock in
Cbltm2Wlan
Homozygous mutant mice died in utero or during ﬁrst 24 h
after birth. CblA/− mice resembled Cbl-knock out animals.
However, the CblA/− mice exhibit additional defects, notably
progressive loss of thymus.
[217]
CblA/− mice display reduced adiposity despite greater food
intake, reduced circulating insulin, leptin and triglycerides
level. The mice are protected against high-fat diet-induced
obesity and insulin resistance.
[179]
Mouse
CblYF (Y737)
Knock in
Cbltm1Dejs
Mice expressing mutant Cbl with inability to interact with the
SH2 domain of phosphatidylinositol (PI) 3-Kinase p85 subunit
exhibit increased bone mass and volume, and decreased
osteoclast function.
[218]
Mouse
Cbl-b (C373A)
Knock in
Cblbtm1Wlan
RING ﬁnger domain mutant mice are healthy and produce
homozygous offspring with expected frequency. Enhanced
high-afﬁnity IgE receptor (FcεRI) signaling in mutant mice is
independent of E3 ligase activity.
[219]
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during embryogenesis in Zebraﬁsh. While loss of Cbl did not alter the
morphogen gradient, Cbl-deﬁcient tissues showed an expansion of
the range of FGF8 target genes that were expressed apparently corre-
lating with reduced lysosomal targeting of active FGFR1 receptor sig-
naling complexes[175]. Thus, Cbl appears to regulate how a critical
developmental morphogen gradient is interpreted by target tissues
and this could have a bearing for the role of mammalian Cbl proteins
as well. It is notable that combined deletion of Cbl and Cbl-b in mice
results in early embryonic lethality through unknown mechanisms
[150]. The elegant genetic studies in model organisms provide strong
evidence that Cbl proteins play a critical role in physiological func-
tions mediated by RTKs and provide a rationale for more directed
studies in mammals.
5.2.2. Studies in mammalian systems
Complementing the evidence frombiochemical andmammalian cell
biological analyses, mousemodels (Table 1) have provided a number of
novel insights into physiological pathways where negative regulation
provided by Cbl proteins is critical. Germ-line deletion of Cbl results in
a series of phenotypes during development and in adult animals.
Cbl-null mice exhibit mild hyper-cellularity of a number of lymphoid
organs, including the bonemarrow and spleen with increased numbers
of megakaryocytes [176], expansion of hematopoietic stem/progenitor
cells in the bone marrow [151], mild increase in mammary ductal
branching in virgin mice [176], altered positive selection of T-cells in
the thymus [177], reduced male fertility [178], lean muscle mass due
to elevated insulin action [179] and other phenotypes; however,
Cbl-null mice appear to live for a relatively normal life span under typ-
ical laboratory housing conditions. Cbl-b-null mice have no apparent
developmental abnormalities. These mice, however, show hyperactive
T cell responsiveness to antigens, leading to autoimmune disease
[180,181], a failure to induce anergy in T cells [149], and reducedmuscle
atrophy in response to unloading [182]. Nonetheless thesemice too live
for a relatively normal life span if infectious challenges are avoided. In
contrast to the mild to moderate phenotypes of individual Cbl or Cbl-b
knockout mice, combined deletion of Cbl and Cbl-b in the germ-line is
associatedwith early embryonic lethality [150]. This ﬁnding is of partic-
ular interest since the embryonic lethality of Cbl/Cbl-b double knockout
mice precedes the time when Cbl-c is ﬁrst expressed in the mid to late
gestation [183], thereby providing clear evidence that Cbl and Cbl-b
play a redundant but essential functional role during embryogenesis.The targets of Cbl proteins thatmediate their embryonic developmental
roles remain to be identiﬁed.
Given the apparently redundant but essential roles of Cbl and
Cbl-b during embryonic development, it is of substantial interest to
dissect out to what extent these two family members (with their clos-
er biochemical similarity compared to Cbl-c) might function redun-
dantly or in a speciﬁc manner. One mechanism for relatively speciﬁc
functions might be provided by their relative expression levels. At
the mRNA level, Cbl and Cbl-b appear to be widely expressed but
with one or the other family member predominating in speciﬁc tis-
sues, which appears to be concordant with the phenotypes of individ-
ual knockouts. For example, higher Cbl expression in the testes and
thymus are consistent with male infertility and T cell developmental
phenotypes of Cbl null mice while hypersensitivity of peripheral T
cells in Cbl-b null mice coincides with higher Cbl-b expression
relative to Cbl [150,178,184]. However, the overlapping expression
patterns in most tissues suggest that either speciﬁc cell types within
these tissues rely on one family member versus the other or that
Cbl and Cbl-b function predominantly in a redundant manner in
many tissues.
Mice with a conditional (ﬂoxed) allele of Cbl on a Cbl-b-null back-
ground have allowed tissue-selective KO of Cbl plus Cbl-b to assess
the question of redundancy and to reveal the full functional impact
of negative regulation by Cbl proteins. Combined deletion of Cbl
plus Cbl-b in peripheral T lymphocytes (using Lck-Cre) indeed led
to a substantially more severe and spontaneous systemic autoim-
mune/inﬂammatory disease and dramatic hyper-responsiveness of T
cells to antigen stimulation [150]. Similarly, Cbl/Cbl-b double deletion
in the B lymphoid compartment of mice led to loss of peripheral tol-
erance [185]. Finally, deletion of Cbl and Cbl-b in hematopoietic stem
cells led to a myeloproliferative disease that was fatal within 8 weeks
of birth [153]. The latter phenotype is replicated by a RING ﬁnger do-
main missense mutant knock-in on a Cbl-null background [152].
Collectively, the KO animal models suggest that Cbl and Cbl-b
proteins serve selective physiological roles likely due to their relative
levels of expression in various tissues. More importantly, these
models have emphasized that the two Cbl-family members Cbl and
Cbl-b function redundantly as essential regulators of both the embry-
onic development and adult tissue homeostasis in mammals. Given
the success of conditional induction of Cbl deﬁciency in a Cbl-b-null
background, further studies using this approach should help elucidate
the roles of these widely expressed Cbl family members in mammals.
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our laboratory) should provide a more facile and deﬁnitive tool to
study functional impact of Cbl plus Cbl-b as redundant but critical
negative regulators at various steps in development and in adult
organ functions. Notably, deletion of the predominantly epithelial
tissue-expressed Cbl-c gene is without a phenotype [183]; however,
combined deletion of Cbl-c with Cbl or Cbl-b has not been examined;
these studies are currently being carried out in our laboratory and
should be of considerable general interest.
5.2.3. Evidence from human diseases
Given the critical roles of PTK signaling in animal development, ho-
meostasis and diseases such as cancer, together with emerging evidence
of the role of Cbl family proteins in animal models, there have been
strong efforts to link aberrations of Cbl family proteins to human disease.
Recent results have indeed linked Cblmutations to a set of humanmalig-
nancies providing unequivocal evidence of the critical role of Cbl family
protein-dependent negative regulation of PTKs and establishing Cbl pro-
teins as tumor suppressors. Since 2007, a number of investigations have
identiﬁed mutations clustered in the helical linker and RING ﬁnger
domain of Cbl (and occasionally of Cbl-b) in about 5% of myeloid leuke-
mia patientswithmyelo-dysplastic syndromes/myeloproliferative disor-
ders: these include the juvenile myelo-monocytic leukemia (JMML),
chronic myelo-monocytic leukemia (CMML) and atypical chronic
myeloid leukemia (aCML) subtypes [186–194]. The cancer-associated
Cbl mutations predominantly involve residues that have been shown
by mutational analyses and/or structural studies to be essential for the
ubiquitin ligase activity of Cbl; those mutants that were examined in
vitro were found to lack the E3 ligase activity [186,195,196]. Further-
more, a cancer-associated mutant introduced into mouse hematopoietic
cells produced mastocytosis [197] and as stated above a RING ﬁnger
knock-in mutant of Cbl in mice phenocopied the myeloproliferative dis-
order seen in human patients as also did the deﬁciency of Cbl and Cbl-b
[152,153]. Findings of a direct link between Cbl-family E3mutations and
human leukemia strongly support the critical role of Cbl protein-
dependent negative regulation of PTK signaling. Identiﬁcation of relevant
target PTKs and a better understanding of the mechanisms of how mu-
tant Cbl proteins promote oncogenesis represent exciting areas of ongo-
ing and future research. Several recent reviews have summarized
progress and emerging trends in this area [62,198–201]. It is somewhat
intriguing that mutations of the linker and RING ﬁnger domains have
thus far not surfaced in solid tumors. Whether this is a reﬂection of a
lower frequency of mutations and need for larger studies or biological
differences in the functional consequences of Cbl protein-dependent
negative regulation in hematopoietic versus other tissues remains to be
determined. Notably, recent studies of Cbl in lung cancer patients identi-
ﬁed several mutations that are located in N- or C-terminal regions but
not in the linker region and the RING ﬁnger domain [202]. As these mu-
tations appear to moderately inhibit Cbl function in cell models, further
studies with other solid tumors are warranted.
Given the growing evidence that human leukemias arise from he-
matopoietic stem/progenitor cells, linkage of Cbl mutations to leuke-
mia also links these proteins to stem/progenitor cell homeostasis.
Animal models with myeloproliferative disease as a result of the
loss of Cbl protein function by gene deletion or knock-in of mutant
Cbl [152,153] further support this role. In this regard, Cbl has also
been shown to negatively regulate the PDGF-dependent survival of
neural progenitor cells, and Cbl and Cbl-b were shown to regulate
the asymmetric distribution of EGFR in neural stem cells as part of
their self-renewal mechanisms [203,204]. Further studies should
help clarify the role (general or limited) of Cbl proteins in stem cell
maintenance and the potential target PTKs that they regulate in
stem cell contexts. In this context, further analyses of the embryonic
lethality of Cbl/Cbl-b double knockout mice should be quite revealing.
Prominent autoimmune phenotypes in mice with Cbl-b (or Cbl
plus Cbl-b) deletion have prompted analyses of polymorphisms/mutations in human patients with autoimmune disease. While sever-
al smaller studies have failed to detect any associations, some recent
studies suggest an association between particular polymorphisms of
Cbl-b with systemic lupus erythematosus [205]. Studies in the
Komeda diabetes prone rat model identiﬁed Cbl-b as a susceptibility
gene but the mechanism by which the truncation mutation in a
region past the RING ﬁnger (and hence unlikely to affect the E3 activ-
ity) might contribute to disease remains unclear [206,207]. Regard-
less of the paucity of evidence in this area, future studies are
warranted especially in view of the clear evidence from mouse
models that aberrant Cbl protein function can contribute to inﬂam-
matory and autoimmune phenomena.
6. Conclusions and future directions
Structural, biochemical and cell biological studies of Cbl proteins
have established that members of the Cbl protein family function as ac-
tivated PTK-selective E3 ubiquitin ligases. Cbl family protein-dependent
ubiquitination targets activated PTKs for degradation either by facilitat-
ing their entry into lysosomes or by promoting their proteasomal
degradation. Signaling intermediates associated with PTK signaling
and/or associated with Cbl proteins also appear to be subjected to
ubiquitination and negative regulation although the role of degradation
needs to be clariﬁed. Cellular and animal studies have established that
at least two members (Cbl and Cbl-b) of the Cbl protein family play
key physiological roles: prominent examples of these roles include pro-
tection against autoimmunedisease and tumor suppressor function, the
latter receiving validation from human studies that have linked muta-
tions in Cbl to human leukemia. Cbl mutations in human leukemia
and insights from animal models together support an important role
of Cbl and Cbl-b in stem/progenitor cellmaintenance. Thus, future stud-
ies of existing and emerging animalmodels and cellularmodels derived
from these, together with studies of additional human pathologies
should help fully realize the range of physiological functions regulated
by the evolutionarily-conserved Cbl protein family.
While functions of the relatively widely-expressed Cbl-family
members Cbl and Cbl-b have begun to be elucidated, the roles of
the structurally distant family member Cbl-c remain unclear. As
Cbl-c is selectively expressed in epithelial tissues, future studies of
this protein by incorporating its deﬁciency in animals that lack Cbl,
Cbl-b or both proteins should help clarify whether this protein func-
tions redundantly with its family members or by itself, perhaps
under speciﬁc physiological conditions. Concurrently, a better linkage
of the roles of Cbl proteins in the early biochemical and cell biological
events associated with activated PTKs and the cellular and organismic
roles deciphered from genetic studies should help underscore the im-
portance of the Cbl protein family and the need for its evolution into a
multi-gene family in mammals. In this regard, systematic examina-
tion of protein-protein interaction networks of all Cbl proteins and
their impact on transcriptional pathways and biological outputs of
PTK signaling under different physiological conditions of cells and tis-
sues should add to our understanding of how Cbl proteins perform
their diverse functional roles.
Studies directed at understanding how Cbl mutants associated
with hematological disorders promote oncogenesis should provide
further avenues to explore the physiological functions of Cbl proteins
as well as provide potential avenues to develop agents that might
prove useful in mutant Cbl-driven human cancer.
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